Biotech News

Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call

Celcuity (CELC)CelcuityEarnings

Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update.

Related news

Celcuity

PAM Pathway Oncology Celcuity develops targeted therapies that inhibit the PI3K-AKT-mTOR signaling network, a pathway frequently involved in treatment resistance and tumor growth. REVTORPYK REVTORPYK, or gedatolisib, is an FDA-approved pan-PI3K and mTORC1/2 inhibitor for certain patients with hormone-receptor-positive, HER2-negative,...

Recent company news

Stock data

Close
56.31 USD
Market cap
4.46B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States